Please review Indications and Usage before proceeding.
INDICATIONS AND USAGE
TEFLARO® (ceftaroline fosamil) is indicated in adult and pediatric patients 2 months
of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms:
Staphylococcus aureus (including methicillin-susceptible and ‑resistant isolates), Streptococcus pyogenes,
Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.
TEFLARO is also indicated in adult and pediatric patients 2 months of age and older for the treatment
of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following
Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with
concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae,
Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEFLARO
and other antibacterial drugs, TEFLARO should be used to treat only ABSSSI or CABP that are proven
or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological
examination should be obtained in order to isolate and identify the causative pathogens and to determine
their susceptibility to ceftaroline. When culture and susceptibility information are available, they
should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local
epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
By continuing, you are confirming that you have read the Indications and Usage.